Track topics on Twitter Track topics that are important to you
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Vaccine therapy may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate the white blood cells to kill tumor cells.
PURPOSE: This randomized phase II trial is studying radiation therapy, vaccine therapy, and interleukin-2 to see how well they work compared to radiation therapy alone in treating patients with prostate cancer.
- Compare immunologic response, as measured by the increase in prostate-specific antigen (PSA)-specific T-cell precursors, in patients with localized prostate cancer treated with vaccine comprising recombinant vaccinia-PSA and rV-B7.1 plus recombinant fowlpox-PSA vaccine, sargramostim (GM-CSF), and low-dose interleukin-2 (IL-2) vs no vaccine regimen.
- Determine the safety and tolerability of this regimen in combination with radiotherapy in these patients.
- Compare the toxic effects of IL-2 in patients treated with these regimens.
OUTLINE: This is a randomized study. Patients are stratified according to planned radiotherapy (irradiation alone vs irradiation and radioactive implant) and planned hormonal therapy (yes vs no). Patients are randomized to treatment arms I or II and, once accrual on these arms is complete, up to 20 patients (9-10 HLA-A2 positive) are accrued to arm III.
- Arm I: Patients receive vaccine comprising recombinant vaccinia-PSA admixed with rV-B7.1 subcutaneously (SC) on day 2. On days 30, 58, 86, 114, 142, 170, and 198, patients receive recombinant fowlpox-PSA vaccine SC. Beginning on day 86, patients undergo radiotherapy 5 days a week with total duration dependent upon whether patient undergoes radiotherapy alone or radiotherapy plus brachytherapy. Patients receive sargramostim (GM-CSF) SC on days 1-4, 29-32, 57-60, 85-88, 113-116, 141-144, 169-172, and 197-200. Patients receive low-dose interleukin-2 SC on days 8-12, 36-40, 64-68, 91-95, 120-124, 148-152, 176-180, and 204-208.
- Arm II: Patients undergo radiotherapy 5 days a week with total duration dependent upon whether patient undergoes radiotherapy alone or radiotherapy plus brachytherapy.
- Arm III: Patients undergo radiotherapy and receive recombinant vaccinia-PSA admixed with rV-B7.1 vaccine and GM-CSF as in arm I. Patients also receive a lower dose of IL-2 SC on days 8-21, 36-49, 64-77, 91-104, 120-133, 148-161, 176-189, and 204-217.
Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 13 years.
PROJECTED ACCRUAL: A total of 48-49 patients (19 for arm I, 11 for arm II, and 18-19 for arm III) will be accrued for this study within 10-15 months.
Allocation: Randomized, Control: Active Control, Primary Purpose: Treatment
aldesleukin, recombinant fowlpox-prostate apecific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine, sargramostim, brachytherapy, radiation therapy
NCI - Center for Cancer Research
National Cancer Institute (NCI)
Published on BioPortfolio: 2014-08-27T03:56:47-0400
RATIONALE: Vaccines made from a person's prostate cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to determine the effectiv...
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or ...
Background: - Flutamide is an approved drug for prostate cancer that blocks the effects of testosterone on prostate cancer cells and may slow the progression of the disease. ...
RATIONALE: Vaccines made from prostate cancer cells may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number ...
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether combining melanoma vaccine with interleukin-2 is more effective than vaccine...
A 78-year-old man with a history of surgically treated prostate cancer and melanoma underwent Ga-prostate-specific membrane antigen (PSMA) PET/CT for biochemical recurrence of his prostate cancer. Thi...
The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prosta...
Radiolabeled ligands targeting prostate-specific membrane antigen (PSMA) are currently being established. Prostate-specific membrane antigen radioligand therapy with Lu-PSMA-617 is a promising treatme...
We report a case of adenocarcinoma prostate treated previously with radical prostatectomy and hormonal therapy who underwent Ga-labeled prostate-specific membrane antigen PET/CT for recurrence evaluat...
Prostate-specific antigen (PSA) is a biomarker for the diagnosis and management of prostate cancer and involved in the development of prostate cancer and/or its progression from the localized to the m...
Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.
The large scale production of pharmaceutically important and commercially valuable RECOMBINANT PROTEINS.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
Techniques utilizing cells that express RECOMBINANT FUSION PROTEINS engineered to translocate through the CELL MEMBRANE and remain attached to the outside of the cell.
The type species of the genus AVIPOXVIRUS. It is the etiologic agent of FOWLPOX.
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells. In vertebrates, it is composed of blo...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...